In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
A groundbreaking new method utilizes RFdiffusion and deep learning to design antibodies that target specific epitopes, revolutionizing antibody therapeutics and enhancing their effectiveness against diseases.
In a bold move, Pfizer has filed a lawsuit against Novo Nordisk and Metsera, claiming their merger violates antitrust laws and threatens competition in the obesity drug market.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
A staggering recall of over half a million blood pressure medication bottles has been announced due to unsafe levels of cancer-causing chemicals. Are you affected? Find out more!
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
In a major move against high prescription costs, AstraZeneca has agreed to sell its drugs at a discount through Medicaid, marking a significant win for the Trump administration's healthcare initiative.
AstraZeneca partners with the Trump administration to offer drastically lower drug prices through Medicaid and the upcoming TrumpRx platform, aiming to make medications more accessible to consumers.
In a significant announcement, President Trump is set to reveal a new drug pricing deal with AstraZeneca, following a similar agreement with Pfizer. This move aims to lower U.S. drug prices and pressure major drugmakers to bring manufacturing back to America. Will it lead to real savings for taxpayers?